1. European School of Thermotherapy April 14-16, 2025 in Rotterdam
The European School of Thermotherapy offers an intensive three-day program focused on the scientific and clinical foundations of hyperthermia treatment - endorsed by ESTRO and ESHO. Distinguished international faculty will present comprehensive coverage of biological mechanisms, physics principles, clinical applications, and recent developments in the field.
Participants will benefit from:
ㆍIn-depth exploration of hyperthermia fundamentals
ㆍClinical workflow demonstrations
ㆍPractical device applications
ㆍDirect interaction with experienced researchers and clinicians
The program includes on-site demonstrations of treatment systems at both Erasmus MC Rotterdam and Amsterdam UMC, providing valuable hands-on exposure to current clinical practices.
This continuing medical education event is supported by heckel and designed for radiation oncologists. medical physicists, radiation therapists, other medical specialists, and researchers seeking to expand their expertise in thermal therapy applications.
2. ESHO 2024 in Malaga: Advancing Hyperthermia Research
The recent Annual Meeting of ESHO (European Society for Hyperthermic Oncology), November 6-8, 2024, showcased significant developments in hyperthermic oncology, with particular emphasis on combined treatment protocols and technical and clinical quality assurance.
The topics with particular relevance for the field of wIRA superficial and whole-body hyperthermia were:
Combined Hyperthermia-Immunotherapy: Novel basic research findings on synergistic effects were presented (e.g., OP-01), alongside clinical implementations, including a noteworthy case report combining CAPOX, Nivolumab, and fever-range whole-body hyperthermia in gastric cancer treatment (FP-37).
Advances in Superficial Hyperthermia: Dr. Notter (Lindenhofspital Bern) and Dr. Thomsen (University Medical Center Freiburg) presented developments in thermography-controlled wIRA superficial hyperthermia, including updates on the ongoing HISTOTHERM study (OP-19). Additionally, T. Lushchaeva (University Medical Center Magdeburg) introduced a prospective study protocol focusing on primary angiosarcoma (FP-16), and D. Marder from Katonspital Aarau presented the development of a phantom for infrared hyperthermia required for quality assurance (FP-15).
Renewed Interest in Extreme Whole-Body Hyperthermia: Preliminary results from an ongoing study investigating extreme WBH in metastatic pancreatic cancer were presented by J.-P. Bogers, ELMEDIX Belgium, developer of a new technology for extreme WBH.
For detailed information, please refer to ESHO_2024_Abstracts.pdf. Abstracts related to wIRA hyperthermia and fever-range applications are OP-01, OP-19, OP-41, FP-10, FP-15, FP-16, FP-33, FP-37 3. New Research: Fever-Range WBH Combined with Checkpoint Inhibitors in GI Tumors
A significant clinical pilot trial investigating the combination of fever-range whole-body hyperthermia (FR-WBH) with immunotherapy has been published in Cancer Med. by Liu P et al. The open-access publication, "Water-filtered infrared A radiation hyperthermia combined with immunotherapy for advanced gastrointestinal tumors," presents promising findings for this therapeutic approach regarding tumor response, enhanced overall safety profile, and improved quality of life.
This research aligns with ongoing investigations in the field, including the POWER study at Charité Berlin, which is examining similar therapeutic combinations (FR-WBH with checkpoint inhibitors) for metastatic malignant melanoma.
4. ThermoRad wIRA: New Clinical Trial at King's College London
Guy's Cancer Center at King's College London has initiated an important clinical trial investigating thermography-controlled wIRA superficial hyperthermia using the hydrosun®TWH1500 system. This prospective study examines the real-world implementation of thermotherapy in conjunction with standard palliative radiotherapy.
Study Population: The trial focuses on three key patient groups:
Patients with superficial inoperable/incurable locally advanced or recurrent/metastatic head & neck squamous cell carcinoma not suitable for radical treatment
Patients with superficial inoperable/incurable locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma not suitable for radical treatment
Cases requiring re-irradiation of locally recurrent breast cancer (LRBC)
Study Details: Principal Investigator: Anthony Kong, MD Clinical Reader and Honorary NHS Consultant in Clinical Oncology Trial Registration: NCT06659146.
This investigation represents a significant step in evaluating the clinical application of wIRA superficial hyperthermia in palliative care settings. The results will contribute valuable data on the integration of hyperthermia with standard palliative radiotherapy protocols.
※본 게시물은 독일 heckel gmbH.에서 발행한 뉴스레터를 전달받아 발행한 것입니다.
